Estrella Immunopharma, Inc. (ESLA) Stock

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

Estrella Immunopharma, Inc. is led by CEO Cheng Liu, publicly traded since 2021.

Estrella Immunopharma, Inc. (ESLA) stock trades at $0.78 with a market capitalization of $33.59M. The stock is valued at a price-to-earnings (P/E) ratio of -2.25, price-to-book of -6.23, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.73 and $3.15, and currently trades 75.2% below its 52-week high.

On profitability, Estrella Immunopharma, Inc. generates a return on equity (ROE) of 167.91% — well above the market average, a sign of a high-quality business, return on capital employed of 251.42%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.estrellabio.com